Table II.
Clinical trial approach | Clinical trial | # OC patients | Objective responses | Reference or Trial ID |
---|---|---|---|---|
Vaccines | Phase II trial of recombinant vaccinia and fowlpox vaccines expressing NY-ESO-1, 2012 | 22 | 21 mos PFS 4 year OS |
90 |
Phase II trial of subcutaneous p53 peptide vaccination, 2012 | 13 | 4.2 mos PFS 41 mos OS |
92 | |
Phase I trial of p53-synthetic long peptide vaccine, 2012 | 20 | No increase in OS | 93 | |
Adoptive Cell Transfers | Phase II trial of p53-pulsed dendritic cells vaccine, 2012 | 6 | 8.7 mos PFS 29.6 mos OS |
92 |
Phase I/II vaccination trial of Her2/neu, telomerase, and PADRE peptide-pulsed DCs ± cyclophosphamide, 2012 | 11 | 90% 3 year OS NED in 6 pts at 3 yrs | 99 | |
Phase I trial of autologous tumor lysate-pulsed dendritic cells + bevacizumab, cyclophosphamide, and autologous tumor lysate-primed T cells, 2013 | 6 | 2 – PR 2 – SD 2 - PD |
100 | |
Pilot study of MUC1-primed cytotoxic T lymphocyte transfer, 2012 | 7 | 1 – CR 6 - PD |
105 | |
Phase I trial of anti-mesothelin CAR T cells, ongoing | N/A | N/A | NCT02159716 | |
Phase I trial of anti-mesothelin CAR T cells + chemotherapy, ongoing | N/A | N/A | NCT01583686 | |
Phase I trial of anti-VEGFR2 CD8+ CAR T cells + chemotherapy, ongoing | N/A | N/A | NCT01218867 | |
Oncolytic viruses | Phase I trial of CA-125- or Na/I symporter-expressing measles virus, ongoing | N/A | N/A | NCT00408590 |
Phase I/II trial of Na/I symporter-expressing measles virus infected mesenchymal stem cells, ongoing | N/A | N/A | NCT02068794 | |
Phase II trial of thymidine kinase-inactivated vaccinia virus, ongoing | N/A | N/A | NCT02017678 | |
Phase I/II trial of oncolytic adenovirus, ongoing | N/A | N/A | NCT02028117 | |
Phase II trial of oncolytic reovirus, ongoing | N/A | N/A | NCT02028117 |
Abbreviations: PD, progressive disease; IR, initial response; CR, complete response; CCR, continued clinical response; PR, partial response; SD, stable disease; NED, no evidence of disease; NR, no response; N/A, not available; PFS, progression-free survival; OS, overall survival.